Deutsche Bank’s Progenics Pharmaceuticals Inc PGNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-30,034
| Closed | -$114K | – | 4609 |
|
|
2020
Q1 | $114K | Sell |
30,034
-2,045
| -6% | -$8.81K | ﹤0.01% | 3192 |
|
|
2019
Q4 | $162K | Sell |
32,079
-22,537
| -41% | -$119K | ﹤0.01% | 3351 |
|
|
2019
Q3 | $275K | Sell |
54,616
-516,535
| -90% | -$2.58M | ﹤0.01% | 2996 |
|
|
2019
Q2 | $3.52M | Sell |
571,151
-766,743
| -57% | -$3.7M | ﹤0.01% | 2016 |
|
|
2019
Q1 | $6.21M | Buy |
1,337,894
+1,149,765
| +611% | +$5.2M | ﹤0.01% | 1710 |
|
|
2018
Q4 | $789K | Sell |
188,129
-314,858
| -63% | -$1.6M | ﹤0.01% | 3037 |
|
|
2018
Q3 | $3.15M | Buy |
502,987
+213,389
| +74% | +$1.64M | ﹤0.01% | 2545 |
|
|
2018
Q2 | $2.33M | Sell |
289,598
-74,927
| -21% | -$572K | ﹤0.01% | 2854 |
|
|
2018
Q1 | $2.72M | Buy |
364,525
+176,527
| +94% | +$1.17M | ﹤0.01% | 2670 |
|
|
2017
Q4 | $1.12M | Sell |
187,998
-195,362
| -51% | -$1.19M | ﹤0.01% | 3127 |
|
|
2017
Q3 | $2.82M | Sell |
383,360
-314,474
| -45% | -$2M | ﹤0.01% | 2313 |
|
|
2017
Q2 | $4.74M | Buy |
697,834
+230,110
| +49% | +$1.7M | ﹤0.01% | 1964 |
|
|
2017
Q1 | $4.41M | Buy |
467,724
+60,652
| +15% | +$605K | ﹤0.01% | 1749 |
|
|
2016
Q4 | $3.52M | Sell |
407,072
-5,328
| -1% | -$39.4K | ﹤0.01% | 1891 |
|
|
2016
Q3 | $2.61M | Buy |
412,400
+130,454
| +46% | +$789K | ﹤0.01% | 2172 |
|
|
2016
Q2 | $1.19M | Buy |
281,946
+127,864
| +83% | +$617K | ﹤0.01% | 2763 |
|
|
2016
Q1 | $671K | Sell |
154,082
-6,756
| -4% | -$30.1K | ﹤0.01% | 3046 |
|
|
2015
Q4 | $985K | Sell |
160,838
-320,650
| -67% | -$2.1M | ﹤0.01% | 2882 |
|
|
2015
Q3 | $2.75M | Buy |
481,488
+224,320
| +87% | +$1.72M | ﹤0.01% | 2261 |
|
|
2015
Q2 | $1.92M | Buy |
257,168
+34,802
| +16% | +$211K | ﹤0.01% | 2487 |
|
|
2015
Q1 | $1.33M | Sell |
222,366
-146,610
| -40% | -$923K | ﹤0.01% | 2712 |
|
|
2014
Q4 | $2.79M | Buy |
368,976
+82,526
| +29% | +$494K | ﹤0.01% | 2416 |
|
|
2014
Q3 | $1.49M | Buy |
286,450
+52,439
| +22% | +$261K | ﹤0.01% | 2727 |
|
|
2014
Q2 | $1.01M | Sell |
234,011
-26,113
| -10% | -$99.7K | ﹤0.01% | 2939 |
|
|
2014
Q1 | $1.06M | Sell |
260,124
-71,258
| -22% | -$364K | ﹤0.01% | 2822 |
|
|
2013
Q4 | $1.76M | Sell |
331,382
-169,238
| -34% | -$745K | ﹤0.01% | 2355 |
|
|
2013
Q3 | $2.51M | Buy |
500,620
+58,659
| +13% | +$318K | ﹤0.01% | 2324 |
|
|
2013
Q2 | $1.97M | Buy |
+441,961
| New | +$1.98M | ﹤0.01% | 2231 |
|
Other funds holding PGNX
Deutsche Bank's PGNX Position: Q2 2020 in Review
Deutsche Bank sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 30,034 shares — an estimated $114K sold.
Deutsche Bank first reported a position in PGNX in Q2 2013 and held it in 28 quarters. The position peaked at $6.21M in Q1 2019. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.
- Deutsche Bank reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
- Deutsche Bank sold 30,034 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $114K.
- Deutsche Bank first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and held it in 28 quarters.
- Deutsche Bank's Progenics Pharmaceuticals Inc position peaked at $6.21M in Q1 2019.
- 3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.
Based on Deutsche Bank's 13F filing for Q2 2020, filed 13 Aug 2020.